加载中
NASDAQHealthcareMedical - Specialties
最新数据
US$20.155
−US$0.315 · -1.54%
Anika Therapeutics, Inc. is a company dedicated to joint preservation, innovating and providing early intervention orthopedic care across the globe, including the United States and Europe. Their core focus areas include osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and advanced bone-preserving joint technologies. All of Anika's products are developed, manufactured, and commercialized utilizing their proprietary hyaluronic acid (HA) technology platform. Their comprehensive product lines feature an OA pain management family, which includes established treatments like Monovisc, Orthovisc, Cingal, and Hyvisc, all designed to alleviate discomfort from osteoarthritis. The company's joint preservation and restoration offerings are extensive, comprising approximately 150 bone-sparing joint technology products, alongside solutions for sports medicine soft tissue repair and orthopedic regenerative therapies. Furthermore, Anika leverages its HA expertise in a non-orthopedic product family, developing applications such as adhesion barriers, advanced wound care products, ophthalmic solutions, and ear, nose, and throat treatments. Anika Therapeutics, Inc. was established in 1983 and is based in Bedford, Massachusetts.
常规交易时段
US$20.155
−US$0.315 · -1.54%
盘中时间采用ET。市场数据可能有所延迟。
Anika Therapeutics, Inc. is a company dedicated to joint preservation, innovating and providing early intervention orthopedic care across the globe, including the United States and Europe. Their core focus areas include osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and advanced bone-preserving joint technologies. All of Anika's products are developed, manufactured, and commercialized utilizing their proprietary hyaluronic acid (HA) technology platform. Their comprehensive product lines feature an OA pain management family, which includes established treatments like Monovisc, Orthovisc, Cingal, and Hyvisc, all designed to alleviate discomfort from osteoarthritis. The company's joint preservation and restoration offerings are extensive, comprising approximately 150 bone-sparing joint technology products, alongside solutions for sports medicine soft tissue repair and orthopedic regenerative therapies. Furthermore, Anika leverages its HA expertise in a non-orthopedic product family, developing applications such as adhesion barriers, advanced wound care products, ophthalmic solutions, and ear, nose, and throat treatments. Anika Therapeutics, Inc. was established in 1983 and is based in Bedford, Massachusetts.
日内区间
当前US$20.155
52周区间
当前US$20.155
盘中时间采用ET。市场数据可能有所延迟。
Anika Therapeutics, Inc. is a company dedicated to joint preservation, innovating and providing early intervention orthopedic care across the globe, including the United States and Europe. Their core focus areas include osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and advanced bone-preserving joint technologies. All of Anika's products are developed, manufactured, and commercialized utilizing their proprietary hyaluronic acid (HA) technology platform. Their comprehensive product lines feature an OA pain management family, which includes established treatments like Monovisc, Orthovisc, Cingal, and Hyvisc, all designed to alleviate discomfort from osteoarthritis. The company's joint preservation and restoration offerings are extensive, comprising approximately 150 bone-sparing joint technology products, alongside solutions for sports medicine soft tissue repair and orthopedic regenerative therapies. Furthermore, Anika leverages its HA expertise in a non-orthopedic product family, developing applications such as adhesion barriers, advanced wound care products, ophthalmic solutions, and ear, nose, and throat treatments. Anika Therapeutics, Inc. was established in 1983 and is based in Bedford, Massachusetts.
日内区间
当前US$20.155
52周区间
当前US$20.155
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 1.13亿 USD | 1.2亿 USD | 1.21亿 USD | 1.14亿 USD | 1.48亿 USD |
| 销货成本 | 4901.2万 USD | 4390.9万 USD | 3826万 USD | 4060.7万 USD | 6485.1万 USD |
| 毛利 | 6380.7万 USD | 7599.8万 USD | 8253.2万 USD | 7322万 USD | 8294.3万 USD |
| 研究与开发 | 2577万 USD | 2554.4万 USD | 2176.3万 USD | 1832.1万 USD | 2732.7万 USD |
| 销售、一般及管理费用 | 4908.8万 USD | 5555.5万 USD | 5992.5万 USD | 5122.9万 USD | 7409.6万 USD |
| 营业费用 | 7485.8万 USD | 8109.9万 USD | 8168.8万 USD | 6955万 USD | 8032.8万 USD |
| 利息收入 | — | — | 231.2万 USD | 65.4万 USD | — |
| 折旧和摊销 | 572.9万 USD | 812.1万 USD | 1421.7万 USD | 1448.7万 USD | 1431.7万 USD |
| 营业利润 | −1105.1万 USD | −510.1万 USD | 84.4万 USD | 367万 USD | 261.5万 USD |
| 净利润 | −1088万 USD | −5638.5万 USD | −8266.7万 USD | −1485.9万 USD | 413.4万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI830.26万0.00%2.3万亿 USD0.03%US$381.09-0.13%
iShares Russell 2000 ETFIWM609.41万0.01%787.4亿 USD0.19%US$276.64-0.45%
Vanguard Extended Market ETFVXF326.1万0.00%954亿 USD0.05%US$232.5-0.44%
U.S. Small Cap Value Portfolio ETF Class SharesDFSV298.44万0.01%268.33亿 USD0.33%US$37.985+0.01%
iShares Russell 2000 Value ETFIWN227.84万0.02%137.49亿 USD0.24%US$210.47-0.29%
Fidelity Small-Mid Multifactor ETFFSMD209.35万0.08%24.9亿 USD0.15%US$49.705-0.29%
Dimensional - US Small Cap ETFDFAS200.26万0.01%338.04亿 USD0.31%US$78.035-0.17%
Schwab U.S. Small-Cap ETFSCHA141.38万0.01%217.13亿 USD0.03%US$32.515-0.44%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFU.S. Small Cap Value Portfolio ETF Class SharesDFSViShares Russell 2000 Value ETFIWNFidelity Small-Mid Multifactor ETFFSMDDimensional - US Small Cap ETFDFASSchwab U.S. Small-Cap ETFSCHAAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
